AGN1 LOEP
Osteoporotic Vertebral Fracture Prevention
Key Facts
About AgNovos Bioscience
AgNovos Bioscience is pioneering a localized, interventional approach to treating osteoporosis by directly rebuilding bone at high-risk fracture sites, diverging from systemic drug therapies. The company's core technology platform delivers a proprietary compound that stimulates new, strong bone formation. With its lead program, AGN1 LOEP, having completed a pivotal study for treating the osteoporotic spine, AgNovos is positioned to address a significant unmet need in a large and growing market. The company is privately held, backed by life science investors, and is advancing towards regulatory submissions and potential commercialization.
View full company profileAbout AgNovos Bioscience
AgNovos Bioscience is pioneering a localized, interventional approach to treating osteoporosis by directly rebuilding bone at high-risk fracture sites, diverging from systemic drug therapies. The company's core technology platform delivers a proprietary compound that stimulates new, strong bone formation. With its lead program, AGN1 LOEP, having completed a pivotal study for treating the osteoporotic spine, AgNovos is positioned to address a significant unmet need in a large and growing market. The company is privately held, backed by life science investors, and is advancing towards regulatory submissions and potential commercialization.
View full company profile